McCarthy Asset Management’s GSK GSK Stock Holding History

McCarthy Asset Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-80	Closed	-$4K	–	135
2022 Q1	$4K	Hold	80	–	–	﹤0.01%	211
2021 Q4	$4K	Hold	80	–	–	﹤0.01%	207
2021 Q3	$4K	Hold	80	–	–	﹤0.01%	216
2021 Q2	$4K	Buy	+80	New	+$3.84K	﹤0.01%	264

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

McCarthy Asset Management's GSK Position: Q2 2022 in Review

McCarthy Asset Management sold out of GSK (GSK) in Q2 2022, closing a stake of 80 shares — an estimated $4K sold.

McCarthy Asset Management first reported a position in GSK in Q2 2021 and held it in 4 quarters. The position peaked at $4K in Q1 2022. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

McCarthy Asset Management reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
McCarthy Asset Management sold 80 GSK shares in Q2 2022, an estimated $4K.
McCarthy Asset Management first reported a position in GSK in Q2 2021 and held it in 4 quarters.
McCarthy Asset Management's GSK position peaked at $4K in Q1 2022.
900 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on McCarthy Asset Management's 13F filing for Q2 2022, filed 20 Jul 2022.